WO2002074955A3 - OLIGONUCLEOTIDES POUR LA REGULATION DU GENE CODANT POUR LE TNFα ET/OU DE GENES SOUS SON CONTROLE ET LEUR APPLICATION - Google Patents
OLIGONUCLEOTIDES POUR LA REGULATION DU GENE CODANT POUR LE TNFα ET/OU DE GENES SOUS SON CONTROLE ET LEUR APPLICATION Download PDFInfo
- Publication number
- WO2002074955A3 WO2002074955A3 PCT/FR2002/000939 FR0200939W WO02074955A3 WO 2002074955 A3 WO2002074955 A3 WO 2002074955A3 FR 0200939 W FR0200939 W FR 0200939W WO 02074955 A3 WO02074955 A3 WO 02074955A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotides
- gene coding
- tnf
- regulating
- constant part
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02718264A EP1402028A2 (fr) | 2001-03-16 | 2002-03-15 | Oligonucleotides pour la regulation du gene codant pour le tnf-alpha et/ou de genes sous son controle et leur application |
CA002440956A CA2440956A1 (fr) | 2001-03-16 | 2002-03-15 | Oligonucleotides pour la regulation du gene codant pour le tnf.alpha. et/ou de genes sous son controle et leur application |
AU2002249332A AU2002249332A1 (en) | 2001-03-16 | 2002-03-15 | Oligonucleotides for regulating the gene coding for tnf$g(a) and/or genes controlled thereby and use thereof |
US10/471,716 US20040138159A1 (en) | 2001-03-16 | 2002-03-15 | Oligonucletides for regulating the gene coding for tnf$g(a) and/or genes controlled thereby and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/03619 | 2001-03-16 | ||
FR0103619A FR2822156A1 (fr) | 2001-03-16 | 2001-03-16 | Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002074955A2 WO2002074955A2 (fr) | 2002-09-26 |
WO2002074955A3 true WO2002074955A3 (fr) | 2003-12-24 |
Family
ID=8861226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/000939 WO2002074955A2 (fr) | 2001-03-16 | 2002-03-15 | OLIGONUCLEOTIDES POUR LA REGULATION DU GENE CODANT POUR LE TNFα ET/OU DE GENES SOUS SON CONTROLE ET LEUR APPLICATION |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040138159A1 (fr) |
EP (1) | EP1402028A2 (fr) |
AU (1) | AU2002249332A1 (fr) |
CA (1) | CA2440956A1 (fr) |
FR (1) | FR2822156A1 (fr) |
WO (1) | WO2002074955A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11484507B2 (en) | 2016-11-02 | 2022-11-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles providing nucleic acids encoding TNF-α |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0375408A1 (fr) * | 1988-12-20 | 1990-06-27 | Baylor College Of Medicine | Méthode de préparation d'oligonucléotides synthétiques se liant spécifiquement à des cibles sur des molécules d'ADN bicaténaire en formant un complexe tricaténaire colinéaire, les oligonucléotides synthétiques et méthodes d'utilisation |
WO1998029430A1 (fr) * | 1996-12-27 | 1998-07-09 | Icn, Pharmaceuticals, Inc. | Oligo-aptameres riches en proteine g et procede de modulation d'une reponse immunitaire |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650316A (en) * | 1994-06-06 | 1997-07-22 | Research Development Foundation | Uses of triplex forming oligonucleotides for the treatment of human diseases |
-
2001
- 2001-03-16 FR FR0103619A patent/FR2822156A1/fr not_active Withdrawn
-
2002
- 2002-03-15 AU AU2002249332A patent/AU2002249332A1/en not_active Abandoned
- 2002-03-15 WO PCT/FR2002/000939 patent/WO2002074955A2/fr not_active Application Discontinuation
- 2002-03-15 US US10/471,716 patent/US20040138159A1/en not_active Abandoned
- 2002-03-15 EP EP02718264A patent/EP1402028A2/fr not_active Withdrawn
- 2002-03-15 CA CA002440956A patent/CA2440956A1/fr not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0375408A1 (fr) * | 1988-12-20 | 1990-06-27 | Baylor College Of Medicine | Méthode de préparation d'oligonucléotides synthétiques se liant spécifiquement à des cibles sur des molécules d'ADN bicaténaire en formant un complexe tricaténaire colinéaire, les oligonucléotides synthétiques et méthodes d'utilisation |
WO1998029430A1 (fr) * | 1996-12-27 | 1998-07-09 | Icn, Pharmaceuticals, Inc. | Oligo-aptameres riches en proteine g et procede de modulation d'une reponse immunitaire |
Non-Patent Citations (10)
Title |
---|
AGGARWAL BHARAT B ET AL: "Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells.", CANCER RESEARCH, vol. 56, no. 22, 1996, pages 5156 - 5164, XP002184657, ISSN: 0008-5472 * |
BULYK M L ET AL: "Quantifying DNA-protein interactions by double-stranded DNA arrays", NATURE BIOTECHNOLOGY, vol. 17, June 1999 (1999-06-01), pages 573 - 577, XP002168458, ISSN: 1087-0156 * |
CHARY-VALCKENAERE I ET AL: "Oligonucleotides: A new resource in rheumatology?", REVUE DU RHUMATISME, (OCT 1998) VOL. 65, NO. 10, PP. 543-545, XP001041724 * |
DATABASE GENE BANK [online] EMBL; 14 November 1997 (1997-11-14), IRAQI, F. ET AL.: "Bos taurus tumour necrosis factor alpha (TNFa) gene", XP002184660, Database accession no. AF011926 * |
DATABASE GENE BANK [online] EMBL; 8 June 1996 (1996-06-08), "Pan troglodytes tumour necrosis factor alpha (TNFa) gene, promoter region", XP002184661, Database accession no. U42626 * |
HERNANDEZ INMACULADA ET AL: "Collagen alpha1(I) gene contains an element responsive to tumor necrosis factor-alpha located in the 5' untranslated region of its first exon.", DNA AND CELL BIOLOGY, vol. 19, no. 6, June 2000 (2000-06-01), pages 341 - 352, XP002242110, ISSN: 1044-5498 * |
IRAQI FUAD ET AL: "Cloning and sequencing of the Tnfa genes of three inbred mouse strains.", IMMUNOGENETICS, vol. 45, no. 6, 1997, pages 459 - 461, XP002184658, ISSN: 0093-7711 * |
KIM, HYUNG-GYOON ET AL: "A Novel Triplex -Forming Oligonucleotide Targeted to Human Cycli D1 (bcl-1, Proto oncogene) Promoter Inhibits Transcription in HeLa Cells", BIOCHEMISTRY (1998), 37(8), 2666-2672, 1998, XP002184659 * |
NEDWIN G E ET AL: "HUMAN LYMPHOTOXIN AND TUMOR NECROSIS FACTOR GENES: STRUCTURE, HOMOLOGY AND CHROMOSOMAL LOCALIZATION", NUCLEIC ACIDS RESEARCH, vol. 13, no. 17, 1985, pages 6361 - 6373, XP002920774, ISSN: 0305-1048 * |
O'DONOGHUE J A: "STRATEGIES FOR SELECTIVE TARGETING OF AUGER ELECTRON EMITTERS TO TUMOR CELLS", JOURNAL OF NUCLEAR MEDICINE, vol. 37, no. 4, SUPPL, 1 April 1996 (1996-04-01), pages 3S - 6S, XP002024863, ISSN: 0161-5505 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002249332A1 (en) | 2002-10-03 |
WO2002074955A2 (fr) | 2002-09-26 |
CA2440956A1 (fr) | 2002-09-26 |
US20040138159A1 (en) | 2004-07-15 |
EP1402028A2 (fr) | 2004-03-31 |
FR2822156A1 (fr) | 2002-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT92640A (pt) | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules by forming a colinear triplex the synthetic oligonucleotides and methods of use | |
EP1156108A3 (fr) | Utilisation de nucléotides d'exo-échantillons dans le clonage de gènes | |
EP1005540A4 (fr) | Proteines ikk-beta, acides nucleiques et procedes | |
EP1419168A4 (fr) | Modulation antisens de l'expression de l'apolipoproteine b | |
WO1998019167A3 (fr) | Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule | |
WO2003014307A3 (fr) | Modulation antisens de l'expression de l'apolipoproteine (a) | |
CA2174315A1 (fr) | Modulation par les oligonucleotides de la proteine associee a la resistance multiples aux anticancereux | |
WO2002036743A3 (fr) | Modulation antisens de l'expression de calreticuline | |
WO2003010284A3 (fr) | Modulation antisens de l'expression de la proteine reactive c | |
WO2003014306A3 (fr) | Modulation antisens de l'expression de la proteine de transfert de l'ester de cholesteryle | |
CA2294566A1 (fr) | Proteines ikk-.alpha., acides nucleiques et procedes | |
EP1724283A3 (fr) | Agonistes du facteur relachant du recepteur 2 de la coritcotropine | |
WO2003008545A3 (fr) | Modulation antisens de l'expression de l'oncogene 2 associe aux gliomes | |
WO2002074955A3 (fr) | OLIGONUCLEOTIDES POUR LA REGULATION DU GENE CODANT POUR LE TNFα ET/OU DE GENES SOUS SON CONTROLE ET LEUR APPLICATION | |
WO2002062951A3 (fr) | Modulation antisens de l'expression de caseine kinase 2-alpha prime | |
BR9910787A (pt) | Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src | |
WO2003030826A3 (fr) | Modulation antisens de l'expression de la proteine 5 de liaison des facteurs de croissance de type insuline | |
WO2004021978A3 (fr) | Modulation antisens de l'expression de la molecule endotheliale 1 (esm-1) | |
WO2003099224A3 (fr) | Modulation antisens de l'expression de la kinesine de type 1 | |
PT1235916E (pt) | Polinucleótidos isolados com um teor reduzido de unidades de controlo epigenético 5'cpg3' e suas utilizações | |
WO2003027229A3 (fr) | Modulation antisens de l'expression de rip2 | |
EP1173458A4 (fr) | Modulation antisens de l'expression de sra | |
WO2004048531A3 (fr) | Modulation de l'expression de la proteine kinase 1 associee a l'apoptose | |
WO2004019283A3 (fr) | Techniques de regulation de la transcription par ciblage d'adn quadruplex | |
WO2003033659A3 (fr) | Modulation anti-sens de l'expression de la metalloproteinase 1 de matrice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2440956 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002718264 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10471716 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002718264 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002718264 Country of ref document: EP |